title: Intraperitoneal Perfusion Therapy of Endostar Combined with Platinum Chemotherapy for Malignant Serous Effusions: A Meta-analysis.
abstract: BACKGROUND
  Malignant serous effusions (MSE) are one complication in patients with advanced cancer. Endostar is a new anti-tumor drug targeting vessels which exerts potent inhibition of neovascularization. This study aimed to systematically evaluate the efficacy and safety of intraperitoneal perfusion therapy of Endostar combined with platinum chemotherapy for malignant serous effusions (MSE).
  
  
  METHODS
  Randomized controlled trials (RCTs) on intraperitoneal perfusion therapy of Endostar combined with platinum chemotherapy for malignant serous effusions were searched in the electronic data of PubMed, EMBASE, Web of Science, CNKI, VIP, CBM and WanFang. The quality of RCTs was evaluated by two independent researchers and a meta-analysis was performed using RevMan 5.3 software.
  
  
  RESULTS
  The total of 25 RCTs included in the meta-analysis covered 1,253 patients, and all literature quality was evaluated as "B" grade. The meta-analysis showed that Endostar combined with platinum had an advantage over platinum alone in terms of response rate of effusions (76% vs 48%, RR=1.63, 95%CI: 1.50-1.78, P<0.00001) and improvement rate in quality of life (69% vs 44%, RR=1.57, 95%CI: 1.42-1.74, P<0.00001). As for safety, there was no significant difference between the two groups in the incidences of nausea and vomiting (35% vs 34%, RR=1.01, 95%CI: 0.87-1.18, P=0.88), leucopenia (38% vs 38%, RR=1, 95%CI: 0.87-1.15, P=0.99), and renal impairment (18% vs 20%, RR=0.86, 95%CI: 0.43-1.74, P=0.68).
  
  
  CONCLUSIONS
  Endostar combined with platinum by intraperitoneal perfusion is effective for malignant serous effusions, and patient quality of life is significantly improved without the incidence of adverse reactions being obviously increased.
authors.affiliation: Department of First Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region, China E-mail : work811@foxmail.com.
authors.forename: Rong
authors.initials: R
authors.lastname: Liang
authors.forename: Hai-Ying
authors.initials: HY
authors.lastname: Xie
authors.forename: Yan
authors.initials: Y
authors.lastname: Lin
authors.forename: Qian
authors.initials: Q
authors.lastname: Li
authors.forename: Chun-Ling
authors.initials: CL
authors.lastname: Yuan
authors.forename: Zhi-Hui
authors.initials: ZH
authors.lastname: Liu
authors.forename: Yong-Qiang
authors.initials: YQ
authors.lastname: Li
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016022:Case-Control Studies; D043169:Endostatins / Q000008:administration & dosage; D006801:Humans; D007263:Infusions, Parenteral; D010477:Perfusion; D010984:Platinum / Q000008:administration & dosage; D016066:Pleural Effusion, Malignant / Q000628:therapy*; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic
chemical_list: D043169:Endostatins; D010984:Platinum